ESSA Pharma Inc. (EPIX) has released an update.
ESSA Pharma Inc. reports promising results from its ongoing clinical trials evaluating the combination of masofaniten with enzalutamide in prostate cancer patients, with a majority showing significant reductions in PSA levels. The company is on track to complete enrollment for its Phase 2 study in early 2025 and expects to provide preliminary data by mid-year, while maintaining sufficient cash to fund operations beyond 2025.
For further insights into EPIX stock, check out TipRanks’ Stock Analysis page.
